The Fibrates Story - A Tepid End to a PROMINENT Drug

Affiliations

¹ From the Health Policy, Quality, and Informatics Program, Health Services Research and Development Center for Innovations, and the Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, and the Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine - both in Houston.

Editorial

Salim S Virani. N Engl J Med. 2022.

. 2022 Nov 24;387(21):1991-1992.

doi: 10.1056/NEJMe2213208. Epub 2022 Nov 5.

¹ From the Health Policy, Quality, and Informatics Program, Health Services Research and Development Center for Innovations, and the Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, and the Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine - both in Houston.

No abstract available

Comment on

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.